Syntara Limited to Present Promising Cancer Trial Results
Company Announcements

Syntara Limited to Present Promising Cancer Trial Results

Pharmaxis Ltd (AU:SNT) has released an update.

Syntara Limited’s interim results from its Phase 2 trial for the myelofibrosis treatment SNT-5055, in combination with ruxolitinib, will be showcased in an oral presentation at the upcoming American Society of Hematology meeting. This recognition highlights the promise of SNT-5055, which has shown encouraging results in tackling bone marrow cancer. Syntara is advancing multiple clinical studies targeting high unmet medical needs, positioning itself as a key player in innovative blood cancer treatments.

For further insights into AU:SNT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Australian Auto-Generated NewsdeskPharmaxis Ltd Highlights Product Pipeline and Risks
TipRanks Australian Auto-Generated NewsdeskSyntara Limited Advances Drug Trials and Financial Strategy
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App